1921
  1. Home
  2. The American Journal of Tropical Medicine and Hygiene
  3. Volume 81, Issue 3
  4. Article
Volume 81, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
Download

Abstract

We investigated whether increasing the period of follow-up or increasing the duration of therapy would markedly alter the 71% cure rate of mucosal leishmaniasis in Bolivia consequent to treatment with miltefosine for 4 weeks. Increasing the follow-up from 12 months to 24 months demonstrated additional relapse in only 2 of 41 patients. Increasing the period of therapy from 4 weeks to 6 weeks only increased the cure rate to 75%. The cure rate of mucosal leishmaniasis in Bolivia, whether 4 or 6 weeks of therapy is used and whether 12 month or 24 months follow up is conducted, is approximately 70%.

Copyright 2009 The American Society of Tropical Medicine
Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2009.81.387
2009-09-01
2020-10-22

  • From This Site

    /content/journals/10.4269/ajtmh.2009.81.387
    dcterms_title,dcterms_subject,pub_keyword
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/14761645/81/3/0810387.html?itemId=/content/journals/10.4269/ajtmh.2009.81.387&mimeType=html&fmt=ahah

References

  1. Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44 : 350–356.
     [Google Scholar]
  2. Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD, 1994. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51 : 77–82.
     [Google Scholar]
  3. Llanos-Cuentas A, Echevaria J, Cruz M, La Rosa A, Campos M, Franke E, Berman J, Modabber F, Marr J, 1997. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 25 : 677–684.
     [Google Scholar]
  4. Romero GA, Lessa HA, Orge MG, Macêdo VO, Marsden PD, 1998. Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow up. Rev Soc Bras Med Trop 31 : 511–516.
     [Google Scholar]
  5. Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ, 2008. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52 : 2855–2860.
     [Google Scholar]
  6. Oliveira-Neto MP, Mattos M, Pirmez C, de Sousa CFS, Junior GG, 2000. Mucosal leishmaniasis (espundia) responsive to low dose of n-methyl glucamine (glucantime) in Rio de Janeiro, Brazil. Rev Inst Med Trop São Paulo 42: 321–325.
     [Google Scholar]
  7. Machado PR, Lessa H, Lessa M, Guimarães LH, Bang H, Ho JL, Carvalho EM, 2007. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44 : 788–793.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2009.81.387
Loading
  • Received : 02 Feb 2009
  • Accepted : 28 May 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error